#3-42E. The Next Frontier: In Vivo RNA Nanotherapies for Arthritis (NatRevRheumatol, 2025)

Are current biological therapies for arthritis reaching their limit due to a lack of specificity? This episode explores a pivotal 2025 review highlighting the emergence of RNA-based nanotherapies as a game-changer for autoimmune and degenerative joint diseases. The paper summarizes breakthrough strategies utilizing lipid nanoparticles (LNPs) to deliver mRNA directly to target cells, including the in vivo generation of tolerogenic antigen-presenting cells via PD-L1 encoding and the endogenous production of anti-CD19 antibodies. The most significant clinical innovation is the ability to induce specific immune tolerance or deplete B cells directly within the patient’s body, effectively bypassing the costly and complex ex vivo cell manipulation required by therapies like CAR-T. However, critical appraisal is essential; these findings are currently derived primarily from murine models of rheumatoid arthritis and lupus, and crucial data regarding the long-term durability of tolerance and potential off-target safety risks in humans remain to be established. For clinicians, this research signals a potential paradigm shift towards "off-the-shelf" precision medicine that could eventually replace broad immunosuppression, necessitating close monitoring of future translational developments.

Citation: Pham, C. T. N. and Guilak, F. Advances in RNA-based nanotherapies for arthritis. Nature Reviews Rheumatology. 2025. DOI: 10.1038/s41584-025-01339-1

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.